Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
5/31/24 19:00 | 5/29/24 | MRNA | Health | BioPrd | Biological Products, (No Diag | Afeyan Noubar | MA | D | 39 | S | -67,135 | 122.06 | 0 | -550 | 15,134 | D | ||||||||||||||||
5/30/24 16:36 | 5/29/24 | MRNA | Health | BioPrd | Biological Products, (No Diag | Mock James M | MA | O | CFO | 6 | S.d | -642 | 110.52 | 0 | -6 | 6 | D | |||||||||||||||
5/30/24 16:27 | 5/29/24 | MRNA | Health | BioPrd | Biological Products, (No Diag | Klinger Shannon Thyme | MA | O | GC | 13 | S.d | -718 | 122.65 | 0 | -6 | 11 | D | |||||||||||||||
5/30/24 16:14 | 5/29/24 | MRNA | Health | BioPrd | Biological Products, (No Diag | Hoge Stephen | MA | O | P | 28 | S.d | -21,680 | 107.44 | 0 | -202 | 1,788 | D | |||||||||||||||
2/16/24 16:10 | 2/16/24 | MRNA | Health | BioPrd | Biological Products, (No Diag | Bancel Stephane | MA | DO | CEO | 25 | S.dm | -276,172 | 145.85 | 0 | -1,894 | 21,075 | D | |||||||||||||||
12/7/23 16:21 | 12/6/23 | MRNA | Health | BioPrd | Biological Products, (No Diag | Garay Arpa | MA | O | Chief Co | 3 | S.d | -394 | 115.04 | 0 | -3 | 4 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |